title: Adiponectin and its receptors in chronic hepatitis B patients with metabolic syndrome in China.
abstract: OBJECTIVE
  Adiponectin can initiate a broad range of metabolic and immunological effects. Little is known about the role of adiponectin in hepatitis B related liver disease and metabolic syndrome (MS).
  
  
  METHODS
  We studied 138 patients with untreated chronic hepatitis B (CHB), who were from Beijing Ditan hospital in 2005 to 2009. According to MS, two groups (65 with MS vs. 73 without MS) were established. They were compared with characteristics and stained immunohistochemically for adiponectin and adiponectin receptor2 (adipoR2).
  
  
  RESULTS
  In the group of CHB patients with MS, the levels of LDH, γ-GT, FPG, FINS, HOMA-IR, HOMA-β, TG and HBeAg positive were significantly higher than those in the group without MS (p<0.05). Liver steatosis in the group with MS is significantly more severe than that in the group without MS (p<0.001). With binary logistic regression analyses, BMI and HOMA-IR showed independent predictors to MS in patients with CHB. In patients with chronic HBV, the insulin sensitizing adipokine adiponectin and its receptor AdipoR2 was associated with diabetes in patients with CHB and MS.
  
  
  CONCLUSIONS
  Our findings showed the CHB patients with MS may be presence of more severe steatosis. MS in CHB patients may be closely correlated with insulin resistance and less effect of viruses. Reduced hepatic expression of adiponectin and adipoR2 might be of pathophysiological relevance in CHB patients with MS.
authors: Beijing Ditan Hospital, Institute of Infectious Diseases, Capital Medical University, Beijing, China.
authors: Xin
authors: X
authors: Li
authors: Na
authors: N
authors: Ren
authors: Wei
authors: W
authors: Ling
authors: Fengxin
authors: F
authors: Chen
authors: Weiyan
authors: W
authors: Zhang
authors: Xiaoling
authors: X
authors: Fan
authors: Meimei
authors: M
authors: Tian
authors: Ting
authors: T
authors: Zhang
authors: Ben
authors: B
authors: Li
authors: Lawrence M
authors: LM
authors: Pfeffer
authors: Hao
authors: H
authors: Wu
authors: Jinqian
authors: J
authors: Zhang
mesh_terms: D052242:Adiponectin / Q000032:analysis* / Q000235:genetics; D000328:Adult; D000704:Analysis of Variance; D015415:Biomarkers / Q000097:blood; D001706:Biopsy; D015992:Body Mass Index; D016009:Chi-Square Distribution; D002681:China / Q000453:epidemiology; D015536:Down-Regulation; D005234:Fatty Liver / Q000453:epidemiology / Q000378:metabolism; D005260:Female; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D007333:Insulin Resistance; D016014:Linear Models; D008099:Liver / Q000737:chemistry* / Q000473:pathology; D016015:Logistic Models; D008297:Male; D024821:Metabolic Syndrome / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000378:metabolism*; D008875:Middle Aged; D012333:RNA, Messenger / Q000032:analysis; D060888:Real-Time Polymerase Chain Reaction; D054419:Receptors, Adiponectin / Q000032:analysis* / Q000235:genetics; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: C499918:ADIPOQ protein, human; C475420:ADIPOR2 protein, human; D052242:Adiponectin; D015415:Biomarkers; D012333:RNA, Messenger; D054419:Receptors, Adiponectin